The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients.

Antipsychotic drugs exert both therapeutic and adverse effects through dopamine D2 receptor (DRD2) antagonism. Genetic variants of this receptor may be responsible for individual variations in neuroleptic response and may therefore be useful in predicting response. In this study we evaluated the role of six polymorphisms of the DRD2 gene in 125 risperidone-treated Chinese schizophrenia patients following the hypothesis that variation in the DRD2 gene could affect drug response. Response was categorized as a change of >40% on the Brief Psychiatric Rating Scale (BPRS). Our results show that genotyping A-241G may help to predict the efficacy of risperidone treatment on the basis that patients with the A allele showed greater improvement than those with the G allele on the overall BPRS (chi2=7.19, p=0.007, p=0.031 after correction by the program SNPSpD), while other polymorphisms, including -141C Ins/Del, TaqIB, rs1076562, T939C and TaqIA, did not show any association with the response to risperidone. These data suggest that the DRD2 A-241G polymorphism or, alternatively, another genetic variation that is in linkage disequilibrium, may influence response to risperidone in schizophrenia patients.

[1]  Laurent Excoffier,et al.  Arlequin (version 3.0): An integrated software package for population genetics data analysis , 2005, Evolutionary bioinformatics online.

[2]  Yong-yong Shi,et al.  SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci , 2023, Cell Research.

[3]  J. Lieberman,et al.  Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations , 2005, Psychopharmacology.

[4]  Jie Xiong,et al.  Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs , 2005, Cell Research.

[5]  J. Scharfetter.  Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update. , 2004, Pharmacogenomics.

[6]  K. Någren,et al.  C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo , 2004, Molecular Psychiatry.

[7]  M. Neville,et al.  Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1 , 2004, Human mutation.

[8]  Laurent Gouya,et al.  The 3′ region of the DRD2 gene is involved in genetic susceptibility to schizophrenia , 2004, Schizophrenia Research.

[9]  E. Noble,et al.  Association of Seven Polymorphisms of the D2 Dopamine Receptor Gene with Brain Receptor-Binding Characteristics , 2004, Neurochemical Research.

[10]  A. Suzuki,et al.  Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[11]  A. Suzuki,et al.  Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatmentresistance to dopamine receptor antagonists in schizophrenic patients , 2003 .

[12]  Abraham Weizman,et al.  DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study , 2003, European Neuropsychopharmacology.

[13]  N. Saitou,et al.  Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. , 2003, Human molecular genetics.

[14]  R. Berecz,et al.  Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[15]  D. Goff,et al.  Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations , 2002, Acta psychiatrica Scandinavica.

[16]  J. Csernansky,et al.  A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. , 2002, The New England journal of medicine.

[17]  Gary Remington,et al.  Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient , 2001, Biological Psychiatry.

[18]  J. Scharfetter.  Dopamine receptor polymorphisms and drug response in schizophrenia. , 2001, Pharmacogenomics.

[19]  T. Kondo,et al.  The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. , 2001, Pharmacogenetics.

[20]  Matthias J. Müller,et al.  Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients , 2001, Schizophrenia Research.

[21]  N. Yasui-Furukori,et al.  Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report , 2001, European Archives of Psychiatry and Clinical Neuroscience.

[22]  E. Hoencamp,et al.  Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial , 2000, Schizophrenia Research.

[23]  R. Love,et al.  Pharmacology and clinical experience with risperidone , 2000, Expert opinion on pharmacotherapy.

[24]  S. Kapur,et al.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.

[25]  D. Lachar,et al.  Use of BPRS-A percent change scores to identify significant clinical improvement: accuracy of treatment response classification in acute psychiatric inpatients , 1999, Psychiatry Research.

[26]  P. Sham,et al.  Model-Free Analysis and Permutation Tests for Allelic Associations , 1999, Human Heredity.

[27]  D. Collier,et al.  Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. , 1998, Pharmacogenetics.

[28]  Yuhei Nakamura,et al.  Functional polymorphism of −141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia , 1998, Psychiatry Research.

[29]  A. Malhotra,et al.  Allelic variation in the promoter region of the dopamine D2 receptor gene influences the antipsychotic response to clozapine , 1998 .

[30]  Hongyu Zhao,et al.  A global survey of haplotype frequencies and linkage disequilibrium at the DRD2 locus , 1998, Human Genetics.

[31]  J O Rinne,et al.  The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers , 1998, Molecular Psychiatry.

[32]  E K Perry,et al.  D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. , 1997, Pharmacogenetics.

[33]  T. Arinami,et al.  A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. , 1997, Human molecular genetics.

[34]  J. Peuskens.  Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol , 1995, British Journal of Psychiatry.